Scil Proteins established a business development operation in California to address increasing demand for the firm’s protein production services in North America. The new organization, headed by Garry Merry, will provide local business support for Scil’s U.S. and Canadian contract manufacturing clients. The firm’s corporate headquarters in Germany will continue to support its Affilin® drug discovery platform, which is available for outlicensing to the biotech and pharma industries.
Scil Proteins operates two business units, Scil Proteins Production and Scil Proteins Pharma. The production business provides full up- and downstream process development for the manufacturing of recombinant proteins in microbial expression systems. Non-GMP process development and premanufacturing services cover the production of pilot batches from research grade to IND grade. The firm has GMP manufacturing capacity to produce quantities of API for clinical development through to market supply.
Scil Proteins Pharma is exploiting its Affilin® drug discovery platform both through licensing deals and through in-house therapeutic development programs, primarily in the fields of inflammation and oncology. Affilin therapeutics are based in the small human serum protein ubiquitin, which is modified through the addition of amino acids at specified sites. Libraries of Affinlin molecules are screened against specified targets, and leads optimized through maturation approaches and fully characterized. The firm claims the resulting molecules bind targets with high affinity and specificity, while demonstrating a low immunogenic potential.